PLRX — Pliant Therapeutics Cashflow Statement
0.000.00%
- $89.62m
- -$235.89m
Annual cashflow statement for Pliant Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -41.5 | -97.3 | -123 | -161 | -210 |
Depreciation | |||||
Non-Cash Items | 4.16 | 13.4 | 22.6 | 41.9 | 43.6 |
Other Non-Cash Items | |||||
Changes in Working Capital | -1.21 | 6.92 | 4.22 | 1.25 | 9.09 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -37.3 | -75.4 | -94.6 | -116 | -156 |
Capital Expenditures | -1.53 | -1.95 | -1.76 | -0.921 | -3.85 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -209 | 75.7 | -148 | -126 | 144 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -211 | 73.7 | -150 | -127 | 140 |
Financing Cash Flow Items | 0 | -0.457 | -0.557 | -0.847 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 213 | 2.53 | 227 | 274 | 23.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -34.9 | 0.783 | -18 | 31 | 7.95 |